Arteriovenous fistula (AV) – Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Arteriovenous fistula (AV) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Arteriovenous fistula (AV) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Arteriovenous fistula (AV): Overview
Arteriovenous fistula (AV) is an abnormal connection between an artery and a vein, in which blood flows directly from an artery into a vein, bypassing some capillaries. Small arteriovenous fistulas in your legs, arms, lungs, kidneys or brain are not much complicated while a large untreated arteriovenous fistula can lead to serious complications. An AV can develop anywhere in the body, though typically occur in the head, neck, spine, and liver. They can be caused from congenital defects or acquired as a results of cardiac catheterization complication, injuries that pierce the skin, and genetic conditions. Arteriovenous fistulas are often surgically created by vascular surgeon for use in dialysis in people with severe kidney disease.
Symptoms
Small arteriovenous fistulas often won't have any signs or symptoms and are usually don't need specialized treatment. Large arteriovenous fistulas may cause signs and symptoms. The symptoms of large Arteriovenous fistula (AV) include:
A diagnosis of Arteriovenous fistula (AV) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Tests to diagnose an Arteriovenous fistula can include: Duplex ultrasound, Computerized tomography (CT) angiogram, and Magnetic resonance angiography (MRA).
Treatment
For small arteriovenous fistula a close monitoring by a doctor is sufficient, these fistula may close by themselves without treatment. Treatment options for large fistula includes endovascular embolization, ultrasound-guided compression, microsurgery, or stereotactic radiosurgery.
Arteriovenous fistula (AV) Emerging Drugs Chapters
This segment of the Arteriovenous fistula (AV) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Arteriovenous fistula (AV) Emerging Drugs
Further product details are provided in the report
Arteriovenous fistula (AV): Therapeutic Assessment
This segment of the report provides insights about the different Arteriovenous fistula (AV) drugs segregated based on following parameters that define the scope of the report, such as:
Arteriovenous fistula (AV): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Arteriovenous fistula (AV) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Arteriovenous fistula (AV) drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Arteriovenous fistula (AV) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Arteriovenous fistula (AV) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Arteriovenous fistula (AV): Overview
Arteriovenous fistula (AV) is an abnormal connection between an artery and a vein, in which blood flows directly from an artery into a vein, bypassing some capillaries. Small arteriovenous fistulas in your legs, arms, lungs, kidneys or brain are not much complicated while a large untreated arteriovenous fistula can lead to serious complications. An AV can develop anywhere in the body, though typically occur in the head, neck, spine, and liver. They can be caused from congenital defects or acquired as a results of cardiac catheterization complication, injuries that pierce the skin, and genetic conditions. Arteriovenous fistulas are often surgically created by vascular surgeon for use in dialysis in people with severe kidney disease.
Symptoms
Small arteriovenous fistulas often won't have any signs or symptoms and are usually don't need specialized treatment. Large arteriovenous fistulas may cause signs and symptoms. The symptoms of large Arteriovenous fistula (AV) include:
- Heartburn or gastroesophageal reflux (backup of stomach contents into the esophagus)
- Purplish, bulging veins that you can see through your skin, similar to varicose veins
- Swelling in the arms or legs
- Decreased blood pressure
- Fatigue
- Heart failure
- bluish tinge on the skin
- Clubbing of fingers
- Coughing up blood
- An arteriovenous fistula in your gastrointestinal tract can cause bleeding in digestive tract
A diagnosis of Arteriovenous fistula (AV) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Tests to diagnose an Arteriovenous fistula can include: Duplex ultrasound, Computerized tomography (CT) angiogram, and Magnetic resonance angiography (MRA).
Treatment
For small arteriovenous fistula a close monitoring by a doctor is sufficient, these fistula may close by themselves without treatment. Treatment options for large fistula includes endovascular embolization, ultrasound-guided compression, microsurgery, or stereotactic radiosurgery.
Arteriovenous fistula (AV) Emerging Drugs Chapters
This segment of the Arteriovenous fistula (AV) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Arteriovenous fistula (AV) Emerging Drugs
- REM-001: Kintara Therapeutics
Further product details are provided in the report
Arteriovenous fistula (AV): Therapeutic Assessment
This segment of the report provides insights about the different Arteriovenous fistula (AV) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Arteriovenous fistula (AV)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Arteriovenous fistula (AV): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Arteriovenous fistula (AV) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Arteriovenous fistula (AV) drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Arteriovenous fistula (AV) R&D. The therapies under development are focused on novel approaches to treat/improve Arteriovenous fistula (AV).
- Arteriovenous fistula (AV) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Arteriovenous fistula (AV) drugs?
- How many Arteriovenous fistula (AV) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Arteriovenous fistula (AV)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Arteriovenous fistula (AV) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Arteriovenous fistula (AV) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kintara Therapeutics
- Enceladus Pharmaceuticals
- Symic Bio
- Vascular Therapies
- C. R. Bard
- Rostaporfin
- Liposome encapsulated prednisolone
- Proteoglycan-like compounds
- Sirolimus-eluting implant
- Lutonix DCB
Introduction
Executive Summary
Arteriovenous fistula (AV): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Arteriovenous fistula (AV) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Arteriovenous fistula (AV) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Arteriovenous fistula (AV) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Liposome encapsulated prednisolone: Enceladus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Rostaporfin - Kintara Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Arteriovenous fistula (AV) Key Companies
Arteriovenous fistula (AV) Key Products
Arteriovenous fistula (AV)- Unmet Needs
Arteriovenous fistula (AV)- Market Drivers and Barriers
Arteriovenous fistula (AV)- Future Perspectives and Conclusion
Arteriovenous fistula (AV) Analyst Views
Arteriovenous fistula (AV) Key Companies
Appendix
Executive Summary
Arteriovenous fistula (AV): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Arteriovenous fistula (AV) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Arteriovenous fistula (AV) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Arteriovenous fistula (AV) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Liposome encapsulated prednisolone: Enceladus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Rostaporfin - Kintara Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Arteriovenous fistula (AV) Key Companies
Arteriovenous fistula (AV) Key Products
Arteriovenous fistula (AV)- Unmet Needs
Arteriovenous fistula (AV)- Market Drivers and Barriers
Arteriovenous fistula (AV)- Future Perspectives and Conclusion
Arteriovenous fistula (AV) Analyst Views
Arteriovenous fistula (AV) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Arteriovenous fistula (AV)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Arteriovenous fistula (AV)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Arteriovenous fistula (AV)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Arteriovenous fistula (AV)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
